Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
Tung-Mao Su, chairman of TPMA, highlights the association’s historic significance in cultivating Taiwan’s pharmaceutical industry, its members’ most pressing concerns, and outlines the developments of the company which he leads…
Ting-Kuo Lee, Academician of Academia Sinica and chairman of the Taiwan Nanotechnology Industry Development Association, explains the history and mission of the association to promote Taiwan’s nano sector and gives…
HB Chen, president of TaiwanBio Therapeutics, introduces the innovative stem cell company and elaborates on their patented cell expansion technique for the production of mesenchymal stem cells (MSC). Chen then…
Katie Lai, associate director of Medpace Taiwan, introduces the company’s history in Taiwan and highlights the CRO’s unique service offering as a partner of choice to the biotech sector. Lai…
Taiwan boasts a booming life sciences sector and is striving to innovate through collaboration. Here we present five of the key executives and stakeholders who are aiming to drive the…
Albert Lu (founder) and Helen Chiu (co-founder) of Tripod Nano Technology (TPNT), introduce the concept of the original innovative manufacturer (OIM) of metal nanoparticle colloidal solutions and highlight the company’s…
Dr Wen-je Ko, mayor of Taipei City, discusses his plans for creating a key biocluster in the city and goes on to share his views on the government’s role to…
Dr Chien-Huang Lin, tenth president of Taipei Medical University, shares his personal mission upon taking the role, elaborates on the research strengths of TMU, and goes on to discuss the…
Dr Fu-Tong Liu, vice president of Academia Sinica, introduces the institution and its research mission of promoting basic research and enhancing translation. Dr Liu goes on to describe Academia Sinica’s…
Betty Li, managing director of PPC, a well-positioned leader in the APAC CRO landscape, speaks about the strategic significance of the group’s Taiwan affiliate and goes on to share her…
Lily Wu, CEO of PapiVax, discusses the biotechs initiative pipeline for the treatment of HPV related diseases and cancers and goes on to elaborate the company’s development and future partnership…
Luke Chen, co-founder and CEO of PuriBlood, speaks about the innovative spin-off technology developed at the R&D Center for Membrane Technology at Chung Yuan Christian University. The company’s leukocyte reduction…
See our Cookie Privacy Policy Here
